Maxim Group analyst Jason McCarthy reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) today and set a price target of $143. The company’s shares opened today at $117.77, close to its 52-week high of $121.96.
McCarthy observed:
“Vertex announced FDA approval of Kalydeco for CF patients age two and older who have one of 23 residual function mutations in the CFTR gene.”
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -11.5% and a 36.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Mateon Therapeutics Inc, and Stellar Biotechnologies.
Currently, the analyst consensus on Vertex Pharmaceuticals is Moderate Buy and the average price target is $120, representing a 1.9% upside.
In a report released yesterday, Morgan Stanley also reiterated a Buy rating on the stock.
The company has a one year high of $121.96 and a one year low of $71.46. Currently, Vertex Pharmaceuticals has an average volume of 1.88M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington’s disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.